Formosa Plastics Corp (台灣塑膠), the flagship entity of Formosa Plastics Group (台塑集團), yesterday said that it would build a new manufacturing site in Texas at a cost of US$207 million.
When completed, the plant would have an annual capacity of 100,000 tonnes of alpha olefins, which are used to make high-density polyethylene (HDPE), among other products, the company said.
About 63,000 tonnes would be used by Formosa Plastics, while the remaining 37,000 tonnes would be sold on the international market, it said.
Photo: CNA
The projected completion date of the plant is October 2025, and mass production is scheduled for December that year after a trial run, the company said.
One of the company’s goals in building the plant in Texas is to secure raw material supply for the production of HDPE, it said, adding that alpha olefins are in high demand worldwide.
Citing a recent report by market information advisory firm IHS Markit, Formosa Plastics said that demand for alpha olefins in North America is expected to hit 915,000 tonnes in 2025, but supply would be only 878,000 tonnes.
The new Texas investment is to be funded by a loan of about US$138 million and capital injection of US$70 million in its fully owned US-based subsidiary Formosa Industrial Corp.
The group has production sites in Texas and Louisiana, where its four major units — Formosa Plastics, Nan Ya Plastics Corp (南亞塑膠), Formosa Chemicals & Fibre Corp (台灣化學纖維) and Formosa Petrochemical Corp (台塑石化) — manufacture petrochemical products such as HDPE, low-density polyethylene (LDPE), ethylene, propylene, polypropylene and ethylene glycol (EG).
The four units on Friday reported mixed revenue results for last month amid China’s anti-epidemic measures, the Russia-Ukraine war and rising inflationary pressure around the world, according to their regulatory filings.
Formosa Chemicals, which manufactures aromatics and styrenics, saw revenue edge up 0.1 percent monthly and 10.2 percent annually to NT$36.42 billion (US$1.23 billion), as price hikes in response to rising crude oil costs offset the impact of lower sales volume.
The other three companies all saw sequential revenue declines, with Nan Ya Plastics registering the biggest drop of 19.7 percent to NT$29.7 billion, as China’s harsh lockdown measures, the Russia-Ukraine war, planned EG production cuts, and changes in consumption caused by inflation affected sales volume and prices.
Compared with April last year, revenue decreased 14.9 percent, said the producer of electronic materials, polyester products, chemical products and plastic products, among others.
Formosa Plastic reported a 5 percent month-on-month decrease in revenue to NT$25.15 billion, but a 3.2 percent increase from a year earlier. The company blamed the monthly revenue drop on declining sales volume of polyethylene and polypropylene.
Formosa Petrochemical, the nation’s only listed oil refiner, reported that revenue dropped 5 percent month-on-month to NT$65.35 billion, as declining sales at its naphtha cracking business offset rising sales at its refining business.
On an annual basis, revenue increased 40.4 percent because of higher product prices this year, the firm said.
In the first four months of the year, Formosa Petrochemical reported the highest annual increase of 41.9 percent in revenue to NT$250.9 billion, ahead of Formosa Plastics’ 13.2 percent increase to NT$96.15 billion, Formosa Chemicals’ 12.5 percent rise to NT$131.82 billion and Nan Ya’s 5.8 percent growth to NT$131.79 billion, companies’ data showed.
Apple Inc might make one out of four iPhones in India by 2025, JPMorgan & Chase Co analysts said yesterday, as the tech giant moves some production away from China, amid mounting geopolitical tensions and strict COVID-19 lockdowns in the country. JPMorgan expects Apple to move about 5 percent of iPhone 14 production from late this year to India, which is the second-biggest smartphone market in the world after China. It is also estimating that about 25 percent of all Apple products, including Mac, iPad, Apple Watch and AirPods, would be manufactured outside China by 2025 from 5 percent currently. The US company
HEADING SOUTH: The US company chose Kaohsiung as its site as more customers, partners and start-ups have expanded their operations to the southern city Qualcomm Inc yesterday inaugurated a new innovation center in Kaohsiung as it steps up efforts to foster local start-ups and a 5G technology ecosystem in the city, following in the footsteps of its local partners. The US chip company’s move fits the Kaohsiung City Government’s plan to build a semiconductor supply chain within the next five years, highlighted by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) first chip plant in the city. TSMC plans to start building the factory by the end of this year, and to start production of 28-nanometer and 7-nanometer chips there in 2024. Qualcomm said it had been
SLUMPING DEMAND: Inventory has climbed by up to 12 weeks as suppliers are under mounting pressure to offload excessive reserves, a TrendForce report said The price of DRAM chips is expected to fall at a steeper rate of 13 to 18 percent next quarter, as high inflation continues to weigh on demand for consumer electronics, causing chip inventories to soar, market researcher TrendForce Corp (集邦科技) said yesterday. The downtrend in DRAM prices could extend from a quarterly decline of 10 to 15 percent in the third quarter, the Taipei-based researcher said. “Demand for consumer electronics continued to stagnate during the third quarter, which used to be a high demand season,” TrendForce said in a statement. “During the quarter, memorychip consumption and shipments both showed quarterly
GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines. GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology. Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research
RSS